Since Mycoplasma genitalium was identified 40 years ago, much of the epidemiology has been described, diagnostic tests have been developed and approved, and recommended treatment approaches have been identified. However, the natural history remains incompletely understood, and antimicrobial resistance has rapidly increased. This review summarizes evidence published since the US Centers for Disease Control and Prevention 2015 Sexually Transmitted Diseases Treatment Guidelines. Data on sequelae remain insufficient, macrolide resistance is common, and fluoroquinolone resistance is increasing. Potential benefits of testing and treatment include resolving symptoms, interrupting transmission, and preventing sequelae. Potential harms include cost, patient anxiety, and increasing antimicrobial resistance.
Manhart LE, Geisler WM, Bradshaw CS, Jensen JS, Martin DH. Weighing Potential Benefits and Harms of Mycoplasma genitalium Testing and Treatment Approaches. Emerg Infect Dis. 2022;28(8):1-11. https://doi.org/10.3201/eid2808.220094
Manhart LE, Geisler WM, Bradshaw CS, et al. Weighing Potential Benefits and Harms of Mycoplasma genitalium Testing and Treatment Approaches. Emerging Infectious Diseases. 2022;28(8):1-11. doi:10.3201/eid2808.220094.
Manhart, L. E., Geisler, W. M., Bradshaw, C. S., Jensen, J. S., & Martin, D. H. (2022). Weighing Potential Benefits and Harms of Mycoplasma genitalium Testing and Treatment Approaches. Emerging Infectious Diseases, 28(8), 1-11. https://doi.org/10.3201/eid2808.220094.
Page created: June 09, 2022
Page updated: July 20, 2022
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.